Thermo Fisher Scientific Inc. $TMO Stake Boosted by NEOS Investment Management LLC

NEOS Investment Management LLC raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 51,364 shares of the medical research company’s stock after buying an additional 11,415 shares during the quarter. NEOS Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $24,913,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Holistic Financial Partners acquired a new position in Thermo Fisher Scientific in the 3rd quarter worth approximately $266,000. Wealthcare Advisory Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.3% in the third quarter. Wealthcare Advisory Partners LLC now owns 2,346 shares of the medical research company’s stock valued at $1,138,000 after purchasing an additional 96 shares in the last quarter. Founders Financial Alliance LLC purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at $351,000. Accretive Wealth Partners LLC raised its position in Thermo Fisher Scientific by 2.3% during the third quarter. Accretive Wealth Partners LLC now owns 3,323 shares of the medical research company’s stock valued at $1,612,000 after buying an additional 75 shares during the period. Finally, Mondrian Investment Partners LTD purchased a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $147,613,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.9%

Shares of NYSE:TMO opened at $504.99 on Tuesday. The stock has a market capitalization of $189.73 billion, a PE ratio of 28.47, a P/E/G ratio of 2.91 and a beta of 0.93. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The firm has a fifty day moving average price of $584.19 and a 200 day moving average price of $545.29. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the company earned $6.10 earnings per share. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has initiated a share buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research reports. Robert W. Baird set a $653.00 target price on Thermo Fisher Scientific in a report on Friday, January 30th. UBS Group reiterated a “neutral” rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. The Goldman Sachs Group initiated coverage on Thermo Fisher Scientific in a report on Tuesday, December 9th. They set a “buy” rating and a $685.00 price objective for the company. Finally, Barclays boosted their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $633.68.

Insider Buying and Selling

In related news, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the transaction, the executive vice president owned 18,731 shares in the company, valued at $11,238,600. This trade represents a 36.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Michel Lagarde sold 32,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the sale, the chief operating officer owned 65,480 shares of the company’s stock, valued at $38,200,377.20. This trade represents a 32.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 108,996 shares of company stock worth $63,355,935. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.